This study tested the hypothesis that the excitatory amino acid transmitters glutamate and/or aspartate are associated with the periaqueductal gray (PAG)-raphe magnus (NRM) projection. Retrograde neuroanatomical tracing procedures utilizing the tracers WGA-HRP or D-[3H]-aspartate were combined with immunocytochemical localization of glutamate or aspartate to determine if glutamate and/or aspartate immunostained neurons projected to the NRM. Both glutamate-and aspartate-immunoreactive cells in the PAG were found to project to the NRM. Double labeling immunocytochemical procedures indicated that glutamate and aspartate are CO-localized in many PAG neurons, suggestifg the following possibilities: (a) one of these two amino acids may serve as a precursor to the other; (b) both amino acids may be CO-released from the same PAG neuron; or (c) both amino acids are present in high lcvels in the perikarya for metabolic purposes. At the EM level, both glutamate-and
Introduction
The midbrain periaqueductal gray (PAG) surrounds the mesencephalic aqueduct and has been suggested to participate in several important brain functions (7,9). One function that has received a great deal of attention over the past two decades is the PAGs involvement in pain modulation. The PAG was originally shown by Reynolds (32) to be an &tiw site for stimulation-produced andgesia, and this was subsequently confirmed by many investigators (see reviews in 5, 16, 17) . Several descending pathways from the PAG participate in pain modulation, but the projection from the PAG to the ventrolateral medulla, terminating in the NRM and adjacent Supported by grants DAO6687, NS19208. and DE06682 from the National Institutes of Health. Prcscntcd in part at thc symposium on EXCITATORY AMINO ACID NEUROTRANSMITTERS AND THEIR RECEPTORS, August 9, 1990. as part of the program at the third joint mccting of the Japan Society of Histochemistry and Cytochemistry and Thc Histochemical Society, held in Seattle, Washington, August 8-11. aspartate-immunoreactive terminals were identified in the NRM, strengthening the concept that both amino acids participate in synaptic transmission in this medullary nudeus.
To determine ifglutamate and aspartate are in fact released from PAG-NRM axons, the PAG was stimulated chemically with homocysteic acid (HCA) and amino acids were collected from the NRM using a miaodialysis probe. Miaoinjection of HCA, but not vehide, into the PAG resulted in the release of both glutamate and aspartate in the nudeus raphe magnus. Thcse data suggest that both glutamate and aspartate are released from PAG fibers terminating in the NRM and provide strong support for the hypothesis that nrcitatory amino acids play a neurotransmitter role in the PAG-KEY WORDS: Excitatory amino acids; Glutamate; Aspartate; Immunocytochcmisuy; Microdidysis; plin modulation; Pcriaqucducd gray; Rats.
NRM p t h~y ,
( JHisroob~a C j T d~a 38d 755-1 765,19po) reticular nuclei, appears to be the key component of this endogenous pain modulation system (5,17). Although the anatomic organization of this pathway has been well documented (1, 15, 19) , its chemistry has only recently begun to be elucidated (10.24). PAG neurons have recently been shown to stain immunocytochemically with antibodies against glutamate, glutaminase, aspartate, and aspartate aminotransferase (12), and behavioral evidence implies excitatory amino acid transmission of the PAG-NRM projection (2). In addition, autoradiographic and electrophysiological data support the hypothesis that an excitatory amino acid transmitter is involved in this pathway (36). It is not clear, however, which excitatory amino acid is involved in the PAG-NRM projection. The purpose of the present study was to define whether glutamate and/or aspartate is associated with this projection and to determine ifeither amino acid is released in the NRM after PAG stimulation.
Materials and Methods
Animals. All animals used in thcse studies were adult (225-350 g) malc Spraguc-Dawley rats. All surgical procedures were performed under ketaminclxylazinc anesthesia (1 ml kctaminc:0.15 ml xylazinc; 0.1 ml/lOO g).
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Immunocytochemistry. Twelve rats were used for light and electron microscopic immunocytochemical localization of glutamate and aspartate in the PAG and NRM. Characterization of the monoclonal glutamate antibody used in these studies has been previously described (26) . The polyclonal aspartate antibody used in these studies was obtained from Dn. P. Petrusz and A. Rustioni and has also been previously characterized (21). Rats were perfused transcardially with 4% paraformaldehyde-0.3% glutaraldehyde in 0.1 M phosphate buffcr (pH 7.2) or with 1% carbodiimide. 1% paraformaldehyde, 0.3% glutaraldehyde, and 0.2% picric acid in phosphate buffer. Animals were post-fixed in 4% paraformaldehyde with or without 0.3% glutaraldehyde.
liznsvcrse sections of midbrain and rostral medulla were cut on a vibratome at 50 pm and incubated overnight at 4'C with either a mouse monoclonal glutamate antibody (diluted 1:8000-1:30,000 in PBS containing 0.1-0.346 Triton X-100) or a rabbit aspartate antiserum (484a2; 1:10,000-1:25,OOO in PBS). Sections were then rinsed in PBS and treated for 1 hr in either biotinylated antimouse IgG (Pel-Freez, Brown Deer, WI; 1:250) or biotinylated antirabbit IgG (Pel-Freez). Tissue sections were then rinsed three times for 5 min in PBS and treated for 1 hr in avidin-biotin-peroxid u e complex (ABC; Pel-Freer). Sections treated with ABC were then rinsed again three times for 5 min in PBS and reacted for 2-6 min with a solution of 3,3'-diminobenzidine (DAB; Polyxienccs, Warrington, PA; 0.5 mglml), H202(0.018%), and 0.05 M 'Gis buffer. Some sections were treated with primary antibodies, rinsed three times for 5 min in PBS and then reacted with colloidal gold-labeled anti-rabbit or anti-mouse secondary antibodies (EY Laboratories; San Mateo, CA).
For co-localization studies, tissue sections were incubated first in either the monoclonal glutamate antibody or the aspartate antiserum and the tissue processed as described above. The DAB reaction was followed by an avidin-biotin blocking step to prevent crossreactivity between markers as previously described (25) . Tissue was incubated for 20 min. After several rinses in PBS, the tissue sections were incubated overnight in normal serum and the alternate primary antibody. Sections were incubated, as above. in biotinylated secondary antibody and ABC. Benzidine dihydrochloride was used as the chromogen for the second marker to produce a blue granular reaction, as previously described (25) . For ultrastructunl co-localization, one primary antibody was visualized with the ABC procedure using a DAB reaction. while the other primary antibody was detected with a colloidal gold-labeled secondary antibody, as previously described (13).
For ultrastructural examination, sections were dehydrated, osmicatcd in 1% os04 for 1 hr, and embedded in Polybed or Spurr's resin, as previously described (13). Selected areas of the raphe magnus were excised and cemented to Epon stubs that had been polymerized in Beem capsules (Polysciences). After 24 hr, ultra-thin sections were cut on a Reichert ultramicrotome and viewed in a Zeiss EM10 transmission microscope.
Controls for immunohistochemical studies included the following: (a) pre-absorption controls were performed by pre-absorbing the primary antibody either with its own antigen or with other amino acids; (b) elimination of primary antisera; (c) elimination of the secondary antisera; (d) elimination of one of the primary antisen in double labeling studies. These controls were also utilized in the combined retrograde transport-immunocytochemical experiments described below.
Combined Reaognde Transport-lmmunocytochcmid Roccdurcs. Five rats were anesthetized and a small deposit of wheat germ agglutinin-honeradish peroxidase (WGA-HRP; Sigma, St Louis, MO) was placed stereotaxically into the raphe magnus as previously described (8,lO) . In four additional animals, 50 nl0fD-[2,3-~H]-aspartic acid was stercotaxically injected ovcr 15 min into the NRM through a g l w micropipette. These latter studies were carried our in collaboration with Drs. L. Wiklund and S. Araneda at CNRS (Gif-sur-Yvette, France).
Animals receiving injections of WGA-HRP were sacrificed 24-48 hr post injection by transcardial perfusion with 60 ml of calcium-free Tyrode's so-lution, followed by 250 ml of 4% puaformaldehyde-0.5% glutaraldehyde. Brains were removed and post-fixed overnight in 5 % glutaraldehyde. Fiftypm midbrain sections were cut on an Oxford vibratome. Tissue sections were incubated in a solution of 0.4% tetramethylbenzidine (TMB; Sigma) with sodium acetate buffer, followed by incubation for 10 min in 0.4% TMB containing 0.3% H202. The TMB reaction product was then stabilized in a solution of DAB, 1% CoC12, and 3% H202 as previously described (8) . This resulted in a blue reaction product in retrogradely labeled cells. After several rinses, first in 'Gis buffer and then in PBS, one set of midbrain sections was incubated with our monoclonal glutamate antibody and the alternate set of sections with the polyclonal aspartate antibody as described above. The immunohistochemical reaction was visualized with a DAB reaction product, resulting in a brown reaction in glutamate-like or aspartate-like immunoreactive neurons. Double labeled cells contained both the blue cqstahnc retrograde " p o r t reaction product and the brown immunocytochemical staining.
After a 15-19-hr survival. D-[ 3H]-aspartate-injected rats were re-anesthetized and perfused transcardially with 1.000 ml of 3.5% glutaraldehyde in 0.1 M Na-cacodylate buffer containing 0.5% Na-metabisulfite (pH 7.4).
The brains were removed and post-fued in the same fixative for 1-6 hr and then transferred to a solution of 30% sucrose in cacodylate buffer. Midbrain sections were cut at 30 pm on a freezing microtome and alternate sections were processed for immunocytochemical detection of glutamate and aspartate, respectively. Immunoreacted sections were then mounted on gelatinized slides, rinsed in distilled water, dehydrated through a series of alcohols, and defatted in xylene. After drying, the mounted sections were dipped in Kodak NTB-2 emulsion diluted 1:1 with distilled water, dried, and exposed for 4-6 weeks in the dark at 6'C with silica gel desiccant. The autoradiographs were dcvcloped in Dektol and fmcd in Nathiosulphate, according to standard procedures (14). Sections were viewed with an Olympus BH2 microscope using both brightfield and darkfield illumination. Double labeled PAG neurons displayed silver grains overlying the cell body, indicative of the ~-['H]-aspartate labeling, and a brown immunohistochemical reaction product within the perikarya, indicative of glutamate-like or aspartate-like immunoreactivity. In addition to the immunohistochemical controls described above, our aspartatc and glutamate antibodies were tested to wure that they did not crossreact with D-aspartate.
Microdialysis Procedure. Twenty rats were anesthetized and implanted with chronic guide cannulas into the PAG and NRM. A stainless steel 23gauge cannula (Small Parts Inc; Miami, FL) was stereotaxically implanted into the ventrocaudal PAG (P, 8 mm caudal to bregma; V, 5.2 mm from the skull surface) approximately 0.5 mm above the site of injection of drugs into this region. The NRM guide cannula was constructed from a piece of 20-gauge stainless steel tubing and was stereotaxically implanted to a depth of 4.5 mm above the target site for the microdialysis probe. Both cannulas were anchored in place using jewelers' screws and cranioplastic powder (Plastics One; Roanoke, VA).
Five to 10 days after the chronic cannula implantation, a microdialysis probe was placed into the NRM via the chronic cannula. The microdialysis procedure used in rhis study is based on the procedure previously described from our laboratories (34). The microdialysis probe was constructed from a piece of 25-gauge stainless steel tubing (Small Parts, Inc) into which the dialysis fiber (200 pm diameter; 5000 molecular weight cutoff; Spectrum Medical Industries, Los Angeles. CA) was inserted approximately 1-2 mm distance and then epoxied into place. The opposite end of the stainless steel tubing was attached to a fluid swivel (Harvard Instruments; South Natick, MA) via a piece of microline tubing (1.5 mm 0.d.; Cole-Parmcr, Chicago, IL) and served as the inflow route for fluid pumped into the probe.
A piece of silica capillary tubing (145 pm 0.d.; Polymicro Technologies, Phoe-I&, AZ) was thmded into the dialysis fiber via a small slit cut in the microline tubing. The opposite end of the silica capillary tubing was attached to the fluid swivel via a piece of PE-IO tubing. The silica capillary tubing served as the outflow route from the dialysis probe. The dialysis system was attached to a peristaltic pump (Rabbit Plus; Rainin Instrument CO, Woburn, MA) and 60.~1 samples were collected via a Gilson microfraction collector. A11 microdialysis experiments were performed in awake, freely moving animals.
Microdialpis experiments were begun after the microdialysis probe had been implanted in the NRM for a period of 24 hr. The microdialysis probe was perfused with Ringer's solution (147 mM NaCI, 4.0 mM KCI, and 2.2 mM CaC12) at a flow rate of 3-5 pllmin for 45-60 min to establish a d f ision equilibrium. After this equilibrium period, samples were collected at 12-min intervals in polypropylene tubes and maintained at I'C until analyzed for amino acids, within 12 hr, by HPLC as described below. The correct location of the dialysis membrane in the NRM and the chronic injecting cannula in the PAG were verified by anatomic examination after each experiment. Only animals with microdialyis probes located in the NRM and chronic injection cannulas located in the ventrocaudal PAG were included in this study.
KCI Depolarization. Initial studies examined the release of amino acids in eight rats under conditions of depolarization with 200 mM KCI. Five or six baseline samples were collected for determination of basal concentrations of amino acids. Depolarization by KCI was achieved by changing the perfusate to a solution confaining 200 mM KCI, 1.2 mM CaC12. and 23.8 mM NaCl for 10 min and then back to Ringer's solution for an additional 60 min. To test whether KC1-induced amino acid release was calcium sensitive, the perfusate was then changed to a solution containing 200 mM KCI, 13 mM NaCI, and 12 mM MgC12. Note that this solution contains 12 mM MgC12 in place of the 1.2 mM CaC12 but that the osmolarity of the solution is maintained by decreasing the NaCl concentration. This solution was perfused through the dialysis system for 10 min. and then normal Ringer's solution was perfused through the system for an additional 60 min. Twelvemin dialysate samples were collected on the Gilson microfraction collector throughout the course of each experiment. The samples were then analyzed by HPLC as described below.
PAG Stimulation. PAG stimulation was accomplished by injecting 0.2 pl of 100 mM of DL-homocysteic acid (HCA) into the ventrocaudal PAG via the chronic injection cannula. Injections were made with a microsyringe over a 30 sec period at a site 500 pm below the tip of the chronic cannula. The dose of HCA administered in this study is based on the report of Bandler et al. (3, 4 ) and on unpublished behavioral data from our lab showing that 100 mM HCA injected into the PAG produces a strong analgesic response in the tail-flick test, whereas 25 or 50 mM HCA produces a much weaker analgesic effect. The advantage of chemical stimulation of the PAG is that it avoids stimulation of fibers of passage that would occur with electrophysiological stimulation.
After collection of four or five baseline samples, an injection of vehicle was made into the PAG and five dialysate samples were collected over the next 60-min. After this 60-min collection period, an injection of HCA was made into the PAG and dialysate samples were collected over the next 72-96 min.
Amino Acid Content Determination. Amino acid concentrations in the dialysate samples were determined using a pre-column o-phthaldialdehyde (OPA; Sigma) derivatization method (23) on a Gilson dual pump HPLC apparatus with Spectrovision fluorometer. OPA was prepared as previously described (34). This solution was mixed with 40 pl of sample and 30 pl of the mixture were injected into the column. A non-liner gradient of 5-85% methanol in sodium acetate buffer (0.05 M, pH 5.9) was used on a C18 reverse-phase column (Phenomena; 250 mm x 4.5 mm) to separate amino acids. Sample concentrations were calculated from known amino acid standard concentrations.
For the KCI data, the concentrations of amino acids in five baseline samples were averaged and compared to average concentration of amino acids in three samples obtained after KCI treatment. For the experiments involving HCA injection into the PAG, the concentrations of amino acids in three samples obtained after HCA injection were averaged and compared to the average concentration of amino acids in three samples obtained after vehicle injection. The concentrations of amino acids measured in each sample collected during the experiment were expressed as a percentage of the average baseline amino acid concentration, which was set at 100%. for the experiment. The KCI and HCA data were analyzed using correlated paired t-tests.
Immunocytochemical Results
Neurons containing glutamate-like or aspartate-like immunoreactivity were found throughout the rostrocaudal extent of the PAG. As indicated in Figures 1A and IC, both glutamate-and aspartateimmunoreactive neurons were more concentrated in the peripheral portion of the PAG. The region adjacent to the mesencephalic aqueduct (the medial subdivision) (7,9) contained fewer immunoreactive neurons. Glutamate and aspartate immunoreactivities were present in all three of the major cell types (triangular, fusiform, and multipolar) found within this region (9). Typically, aspartate-immunoreactive neurons appeared to display higher intensities of staining throughout the PAG than glutamate-i"unoreactive cells (compare Figure 1B with Figure ID) . Because the distribution of aspartate-and glutamate-immunoreactive neurons was very similar, double labeling experiments were performed to determine if the immunostaining for these two amino acids was co-contained within PAG neurons. The results of these experiments indicated that the majority of PAG neurons containing glutamatelike immunoreactivity also contained aspartate-like immunorcactivity (Figure 2 ). Ultrastructural examination of the PAG also demonstrated double labeled perikarya and dendrites (Figures 2C and 2D) . Double labeled neurons were found throughout the rostrocaudal extent of the PAG and were present in all four PAG subdivisions (7, 9) .
Combined Retrograde Transport-Immunocytochemzcal Experiments
Although many PAG neurons were found to contain glutamate and aspartate, it was not possible to determine from immunocytochemical staining alone whether any of these neurons project to the NRM. To determine this, immunocytochemical staining was combined with retrograde transport of WGA-HRP. Injections of WGA-HRP into the NRM resulted in the presence of many retrogradely labeled cells in the PAG, as previously reported (10.37). Midbrain sections processed for visualization of both the retrograde tracer and glutamate or aspartate immunoreactivity displayed a large number of double labeled neurons in the PAG ( Figure 3A) . Neurons containing WGA-HRP and glutamate immunoreactivity ( Figure   3B ) and neurons containing WGA-HRP and aspartate immunoreactivity were evident in the vcntrocaudal PAG, and to a lesser extent in the dorsal PAG.
To confirm that glutamateor aspartate-immunoreactive PAG neurons that projected to the NRM were in fact excitatory amino The immunoreactive terminal in D arises from an unmyelinated immunoreactive axon (small anow) located at the top of the micrograph and forms an asymmetric synaptic contact (large a r m ) with an unlabeled dendrite. The dendrite also receives synaptic input from an adjacent unlabeled terminal (U). An aspartate immunontacti dendrite (d) is also present in E. Bars -05 Gm.
brain sections approximately 97% of D-[ jH]-aspartate retrogradely labeled neurons were found to contain aspartate-like immunoreactivity. An example of a ~-[~H]-aspartatc retrogradely labeled PAG neuron which also exhibits glutamate immunoreactivity is illustrated in Figure 3C , while a ~-[~H]-aspartatc-labclcd PAG ncuron which displays aspartate immunoreactivity is shown in Figure  3D . The silver grains overlying the neuron indicate the D-[~H]aspartate labeling. while the homogeneous gray staining of thc cytoplasm indicates the immunohistochemical reaction product. Further details of the results of these combined ~-[~H]-aspartateimmunocytochemical experiments will be reported ckcwhcre (submitted for publication).
Ultrastructural Localization of Glutamate and Aspartate in the Raphe Magnus
Although glutamate and aspartate immunoreactivity was localized in the perikarya of PAG-NRM ncurons, it was important to determine if these amino acids were also present in axon terminals in the NRM. Ultrastructural examination of rostral medullary sections processed for glutamate or aspartate localization revealed the presence of glutamate and aspartate immunoreactivity in axons and axon terminals in the NRM. Approximately 40% of myelinated axons in the NRM region contained glutamate-like immunoreactivity on glutamate-immunormted tissue sections, and approximately 52% of myelinated axons displayed aspartate-like immunoreactivity on tissue sections immunoreacted for aspartate ( Figure 4A ). Aspartate and glutamate immunostaining was also observed in unmyelinated axons in this region (Figure 4D) . Aspartate-and glutamate-immunoreactive axon terminals displayed similar ultrastructural characteristics in the NRM. The terminals were usually elongated ( Figure 4B and 4D) or round (Figure 4C and 4E), contained round, clear vesicles. and formed asymmetric synapses (Figures 4C and 4D) .
Micmdralysis R e d s
The mean basal concentration of amino acids in the dialysate samples obtained from the NRM in eight rats were found to be 2.33 f 0.67 ng of g h " t e . 0.26 f 0.06 ng of aspartate, 5.09 f 0.81 ng of glycine. and 1.48 0.14 ng of taurine. Glycine and glutamate were present in the highest concentrations in the dialysis samples, whereas aspartate was present in lowest concentrations. The basal concentration of glutamate was 8-10 times that of aspartate. In more recent experiments, we have also begun to measure the concentration of GABA in our dialysate samples. The mean basal concentration of GABA in the dialysate was less than 0.1 ng (0.086 f 0.03 ng) and thus it is present in the NRM dialysate in lower concentrations than glutamate, aspartate, glycine. and taurine. Pcrfusion with KCI increased the concentration of glutamate by 168%. of aspartate by 145%, and of taurine by 163%. as shown in Figure   5 . The concentration of glycine was not signifiiantly increased after treatment with KCI. When the CaCl2 in our KCI solution was replaced with MgC12, this prevented the increase in glutamate and aspartate in the dialysate (Figure 5) . suggesting that the m l e w of these amino acids is calcium dependent. The addition ofMgc12 reduced but did not prevent the increase in taurine release caused by KCI (Figure 5) .
After an injection of 100 mM HCA into the ventrocaudal PAG, the concentration of aspartate in the dialysate was found to increase by 253.8% compared to the injection of vehicle in the same animal (Figure 6) . The concentration of taurine in the dialysate samples increased 158% and the concentration of glutamate increased 56% after HCA injection into the PAG. By contrast, the concentration of glycine in the dialysate after HCA injection increased only by 33.6%. and this increase was not statistically significant compared with the concentration in the dialysate after injection of vehicle into the PAG.
Discussion
The present study was designed to test the hypothesis that glutamate andlor aspartate are neurotmnsmittecs vsociated with the PAG-NRM projection in the rat. lmmunohistochcmid analysis revealed the presence of glutamate-and aspartate-immunoreactive neurons in the PAG. and double labeling studies suggested that a majority of PAG neurons that displayed glutamate-like immunostliniog also m-contained v p v n t e immunoreactivity. The rctrogmde "port-immunocytochemical experiments indicated that a population of PAG neurons containing glutamate or aspartate immunomctivity projms to the nucleus raphe magnus. Because the retrograde ~-[~H ] -l s p u t a t c procedure selectively labels atcitatory amino acid-projming neurons (6,14,36) , the results ofthe combined retrograde D-[ 3H]-aspartate-immunocytochemical acperi- ments imply that both glutamate and aspartate are transmitter candidates in the PAG-NRM pathway. Howcvcr, the significance of the perikaryal contents of glutamate and aspartate is far from obvious, as discussed below. Therefore, firm conclusions regarding the nature of the amino acid transmitter associated with t h e e retrogradely labeled cells cannot be made simply on the basis of the immunostaining of PAG cell bodies. Electron microscopic studies, on the other hand, revealed the presence of both glutamate-and aspartate-immunoreactive terminals in the NRM, which supports a neurotransmitter role for these two amino acids in this region. Finally, the microdialysis studies provide the strongest support for glutamate and aspartate as transmitters of the PAG-NRM pathway, since both amino acids are released in the NRM after PAG stimulation.
Observations of various brain regions from several laboratories have suggested that idenufrcation of putative glutamatergic or aspartatergic neurons can be pursued by immunocytochemistry (see Discussion in 8). Howcvcr, the functional interpretation of immunolabeling is complicated by the fact that glutamate and aspartate also serve metabolic roles. In fact, the metabolic pools of glutamate and aspartate may be equal to or may exceed the sizes of the respective transmitter pools in terms of total brain content (18). This may be particularly relevant with respect to glutamate at the lml of the neuronal perikaryon. which is distant from the site of transmitter release and in which the amount of glutamate i"unostaining may be more closely related to the size of the metabolic pool than to that of the transmitter pool (27.38) . The intensity of glutamate and aspartate immunostaining varied from neuron to neuron in the PAG, which probably reflects different concentrations of these two amino acids among PAG neurons. Whether the most intensely immunostaincd PAG cells reflect neurons that utilize glutamate or aspartate as transmitter substances, or simply indicate neurons that utilize a large amount of these two amino acids for metabolic purposes, is a difficult question to answer on the basis of our present state of knowledge.
Co-localization of glutamate and aspartate in PAG neurons is not surprising, because the neurons in this region also exhibit immunostaining for the enzyme aspartate aminotransferase ( A A k e ; 12), which converts aspartate to glutamate in a reversible manner. Co-localization of glutamate and aspartate occurs in many neuron populations throughout the central nervous system (21.28.35.38) . although the ratio between glutamate immunoreactivity and aspartate immunoreactivity varies considerably among neurons (38). At this point it is not clear whether one amino acid serves as the precursor to the other. whether both amino acids serve metabolic roles in the perikarya, or whether both amino acids serve transmitter roles within the same cell. The significance of the co-localization of these two amino acids may be highly dependent on the location and function of the perikarya within the CNS. For instance, Palaiologos and co-workers (29) have recently shown that A A k e functions to supply the transmitter glutamate in cultured cerebellar granule cells, presumably by converting aspartate to glutamate. Bccause glutamate immunoreactivity is more intense in cerebellar granule cells than aspartate immunoreactivity (13), the immunostaining pattern is consistent with glutamate as the putative transmitter of these cerebellar neurons. In the perihypoglossal nuclei. on the other hand, there is a high ratio of aspartate immunoreactivity compared with glutamate immunoreactivity (38). which may signify a preferential release of transmitter aspartate or simply an abundance of metabolic aspartate. Within the PAG, aspartate-immunoreactive neurons typically stain more intensely than glutamate-immunoreactive neurons; however. the relevance of this difference in intensity is not clear because different antibodies (rabbit vs mouse) and different dilutions of antibodies were used. It is interesting however, that there was a greater increase in the release of aspartate in the NRM after PAG stimulation than in the release of glutamate in our microdialysis studies. Therefore, the increased aspartate immunostaining in PAG neurons may have some relevance to transmitter release.
The localization of glutamate and aspartate in mons and synaptic terminals in the NRM is certainly consistent with a transmitter role for these two amino acids in the NRM. Unfortunately. straight immunocytochemical localization does not allow us to associate these immunoreactive terminals with axons arising from the PAG. However, preliminary studies from our laboratory using the anterograde tracer Pbuseolus vulguris agglutinin (PHA-L) indicate that some PAG terminals in the NRM (which were labeled with PHA-L after injections of this tracer into the PAG) also contain aspartate-like immunoreactivity. These data support the hypothesis that aspartate may be a transmitter released from PAG terminals in the NRM. Whether PAG terminals also contain glutamate immunoreactivity remains to be determined.
Finally, the strongest support for the involvement of aspartate and glutamate in the PAG-NRM pathway is derived from the pres-ent microdialysis experiments. Both glutamate and aspartate are released in the NRM after KCI stimulation and this release is calcium sensitive o n the basis of results of the experiments in which the calcium in the KCI solution is replaced with high magnesium. Thus, KCI caused a 168% increase in the concentration of glutamate and a 145% increase in the concentration of aspartate in our dialysate samples compared to baseline. Because the potassiumevoked efflux of these two transmitter amino acids was calcium dependent, it was considered to reflect release from the transmitter pool (31, 33) . On the other hand, the potassium-evoked efflux of taurine was only partially calcium sensitive, which is consistent with many nontransmitter roles for this amino acid (22) . Preliminary data also indicate that glutamate and aspartate concentrations are increased in the NRM dialysate after a 10-min perfusion through the dialysis system with 200 pM veratridine, which is also consistent with relcasc of glutamate and aspartate from a transmitter pool. Thus the demonstration of aspartate-like and glutamate-like immunoreactivities in axon terminals in the NRM, coupled with the microdialysis data demonstrating calcium-dependent, potassiumevoked release of these two amino acids, provides strong support for their participation as transmitters in the raphe magnus.
The chemical stimulation-microdialysis paradigm used in the present study is similar t o that used by Palmer and co-workers (30) in the neostriatum. Palmer and colleagues administered NMDA or GABA antagonists in the frontal cortex and examined the release of aspartate and glutamate in the neostriatum using microdialysis. In the present study we administered the excitatory amino acid agonist HCA into the midbrain PAG and examined the release of glutamate and aspartate from the NRM. The concentration of aspartate showed the greatest change (253.8%) in our microdidysate samples compared with vchicle-injected controls after PAG stimulation. This implies that aspartate may be the more important transmitter in the PAG-NRM pathway. On the other hand, although glutamate increased only 56% in the dialysate after HCA injection into the PAG compared with the vehicle-injected control, it is important to keep in mind that the baseline concentration of glutamate in the dialysate is 10 times higher than aspartate. Thus, a 56% increase in glutamate concentration is actually greater in terms of total amino acid concentration than a 253% increase in the concentration of aspartate.
In addition, it should be noted that glutamate has a higher binding affinity than aspartate at excitatory amino acid receptors (20). Thus, less glutamate than aspartate is required to activate excitatory amino acid receptors, and this may be one possible explanation for the increased release of aspartate vs glutamate after PAG stimulation. One other complicating factor is the fact that the results obtained with microdialysis are only reflections, and not correct values, of the brain interstitial concentration of the amino acids of interest (11). Despite these variables, it seems likely that both glutamate and aspartate are released from PAG axons in the NRM after PAG stimulation. These results are consistent with previous electrophysiological (36) and behavior studies (2) which have implicated an excitatory amino acid transmitter in the PAG-NRM pathway. Whether or not these two amino acids exhibit differential release in the NRM in response to changes in the participation of the PAG in various behavioral states of the animal remains to be determined. 
